Correlation between Apoptotic and Anti-apoptotic Proteins (caspase-3 and Bcl2) in Chronic Hepatitis C: An Immunohistochemical Study
|
|
|
- Leonard Booker
- 10 years ago
- Views:
Transcription
1 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October Correlation between Apoptotic and Anti-apoptotic Proteins (caspase-3 and Bcl2) in Chronic Hepatitis C: An Immunohistochemical Study Samia El-Naggar and Sahar Aly Daoud Pathology department, Faculty of medicine, Beni -Sueif University, Egypt ABSTRACT There is increasing evidence suggesting that liver cell damage in chronic HCV infection is mediated by induction of apoptosis. The morphological alterations of apoptosis are mediated by a family of intracellular proteases called caspases. Caspase- 3 is the central executioner of many if not all apoptosis pathway. The aim of the work of the present study is to analyze the apoptotic like protein caspase-3 and anti-apoptotic Bcl2 expression in tissues from patients with chronic HCV to throw more light on apoptotic process and their correlation with histopathological changes. Material and Methods: Liver biopsies from 73 patients with chronic HCV (40 patients with history of bilharziasis, 33 patients with no history of bilharziasis) selected from those referred to tropical medicine department, Beni Sueif University hospital before taking treatment, examined by H&E and immunostained for caspase-3 and Bcl2. Results: There was positive correlation between caspase-3 and the grade of activity; as well as the stage of fibrosis in cases with HCV of both groups (those associated and not associated with bilharziasis). While, Bcl2 was not expressed by liver cells. Conclusion: Finding that the anti-apoptotic protein Bcl2 was not expressed in hepatocytes in patients with chronic hepatitis C selected for our study leads to the conclusion that in these cells apoptosis is not inhibited by this protein, fact that could explain the increased apoptosis observed in liver samples from these patients. In addition caspase-3 is a noninvasive measure for detection of early liver cell injury and fibrosis. INTRODUCTION In the last years, infection with hepatitis C virus is prevalent around the world and for more than 80% of cases leads to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. (Tran, 2008) There is a great degree of variation in the prevalence, ranging from less 1% in the United Kingdom to more than 20% in Egypt. In the developed world, the relatively low incidence is mostly due to intravenous drug abuse, while the World Health Organization (WHO) anti- Schistosomal vaccination program in Egypt 1970s and other vaccination programs in Mongolia and Bolivia have led to much higher rate in those countries.(frank, et al., 2000) These figure are alarming, since patients currently asymptomatic with relatively mild disease will eventually progress to end stage liver disease and develop hepatocellular carcinoma (HCC).Moreover, there is no proper vaccine against HCV and anti-viral treatment is not only expensive but relatively toxic, sufficiently ineffective in treating all patients. (Pearlman, 2004) This underscores the need for more effective therapies. A better understanding of the mechanism underlying the pathology of the chronic HCV infection could be helpful in identifying a novel therapeutic target against this disease. The mechanisms by which liver cell inflammation, fibrosis and sign for chronic hepatitis appear are not completely understood. Many studies suggest that apoptosis may be involved in the pathogenesis of chronic hepatitis C. (Bantel and Schultze-Osthoff, 2003), (Fisher et al, 2007). Apoptosis is a complex phenomenon that occurs through two main pathways: extrinsic (mediated by death receptors) and intrinsic (mitochondrial pathway) that converged to final common way involving activation of caspases.(hengartner, 2000 and Gupta, 2003) The intrinsic pathway of apoptosis is initiated within the cell mitochondria; playing an important role. The instability of the mitochondrial membrane induces the release of proapoptotic factors into cytosl, such as cytochrome C, leading to activation of downstream caspases; enzymes responsible for degradation of several cellular changes that define apoptotic cell death. Several intracellular proteins are involved in the regulation of apoptosis constitute the caspase family and in
2 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October particular, the Bcl-2 family of proteins, which includes both pro- and antiapoptotic members; are perhaps the most important regulators of the intrinsic pathway. These proteins act upstream and at the level of the mitochondria to integrate death and survival signals, and the balance between pro- and antiapoptotic members of the family, as well as their reciprocal interactions, determines whether or not the intrinsic pathway of apoptosis is initiated.(garrido et al, 2006 and Rasola, 2007) Aim of the work The aim of the present work is to analyze the apoptotic like protein caspase-3 and antiapoptotic Bcl2 expression in tissues from patients with chronic HCV to throw more light on apoptotic process and their correlation with histopathological changes. MATERIAL & METHODS The current study was carried on 73 patients with chronic HCV selected from those referred to tropical medicine department, Beni Sueif University hospital before taking treatment. Patients with co-infection of other viruses such as HBV, HDV, HIV infection, patients using hepatotoxic drugs, herbal medication within 6 months prior to liver biopsy, patients having diabetes mellitus or hyperlipidemia were excluded. Demographic data (age, gender, and clinical symptoms), biochemical data (aspartate aminotransferase AST, ALT) and serological findings as viral load were recorded. Two pathologists reviewed liver biopsies. Cases were divided into two groups: Group I: Included 40 HCV with history of schistosomiasis. Group II: included 33 HCV with no history of schistosomiasis. Liver biopsies were included in paraffin, processed and cut at 3 µm sections were used for Hematoxylin and Eosin (H&E) stains for histopathological diagnosis, Masson trichrome stain for detection of fibrosis and other sections were fixed on adhesive slide for immunohistochemical staining. Examination of sections stained with Hematoxylin and Eosin (H&E): Several histological features were evaluated as follows: Histological grading of necroinflammatory score based on modified HAI grading by Ishak et al.,(1995) including interface hepatitis (0-4), focal spotty necrosis (0-4), confluent necrosis (0-6) and portal inflammation (0-4). Grades of activity 1-3 were considered minimal, grades 4-8 were considered mild, grades 9-12 were considered moderate and grades were considered severe. Degree of steatosis 0: absent 1 : < 33% 2: 33-66% 3: > 66 Presence of portal lymphoid follicles, presence of bile duct damage (lymphocytic intraepithelial or periductuler infiltration), the involvement pattern in each portal tract ( total involvement > 80%, partial involvement < 80% or no involvement) the knodell histology activity index and fibrosis score of Ishak modified HAI.(Ishak 1995) were also evaluated. Histological staging of fibrosis of chronic hepatitis was done according to fibrosis score (0-6). (Ishak et al.,1995) Immunohistochemical staining for caspase-3 and Bcl2 was performed using the following primary antibodies: polyclonal rabbit caspase-3 diluted (1:50) and monoclonal mouse anti-bcl2, diluted 1:75 (Dako) followed by incubation with appropriate secondary antibody. We use avidinbiotin-peroxidase complex (Vector laboratories) to amplify the reactions and 3, 3'- diaminobenzidine hydrochloride/h2o2 (Sigma Aldrich Co.) to develop them. Nuclear counterstaining was done with Meyer's hematoxylin. The expression of caspase-3 was measured in 10 successive high power fields (x400). It was expressed as brown coloration in hepatocyte cytoplasm. The degree of caspase-3 expression within the hepatic lobules was evaluated semiquantitatively according to the percentage of positively stained cells and classified into four groups. (-)= no immunostaining, (+) = (<25%of cells), (++) = (25%-50cells), (+++) = (>50%- 75% of cells), (++++) =>75%of cells. (Bantel et al 2001). Positive immunostaining expression of Bcl2 was considered if brownish granules in the cytoplasm or in the nucleus of different cells were expressed. A semi-quantitative analysis was
3 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October performed after examination of five microscopic fields (X400) on each slide, assignment of scores, based on the number of positive cells identified. The score was +: up to 5 positive hepatocyte per field, ++: 5-10 positive hepatocytes per field.(borner 2003) Statistical analysis was performed using windows soft ware. The relation was obtained by Pearson Chi- square test. P value less than 0.05 was considered significant. RESULTS According to age of the present studied cases; mean age in group I was 43y and group II was 48y. As regards sex distribution: male to female ratio in group I was 2:1 and 3:2 in group II, the difference between groups of patients in age and sex distribution was statistically insignificant (P= and P= 0.086) respectively. Histological examination of liver biopsies done on group I revealed minimal activity in 10 cases, mild activity in 7 cases, moderate activity in 11 cases, severe activity in 12 cases. As regard group II: we found minimal activity in 3 cases, mild activity in 10 cases, moderate activity in 5 cases, severe activity in 15 cases. <5% steatosis was found in 18 cases(45%) in group I and 13 cases(39%) in group II. Immunohistochemical stains for detection of caspase-3 and Bcl2: Expression of the two apoptotic protein caspase- 3 and Bcl2, which are involved in apoptosis execution and anti-apoptotic function, respectively, were assessed. There was no significant correlation between Caspase-3 with any of the histological features. Immunohistochemical assessment of caspase-3 and activity in liver biopsy specimens was shown in (table1): The grading of caspase-3 activity was expressed as percentage of positively stained cells. Minimal activity was found in (25%). Mild activity was found in (17.5%), moderate activity was found in 27.5%, marked activity was found in (30%) of liver biopsy in group I. In group II, minimal activity was found in 9.1% of cases. Mild activity was found in 30.3% of cases, moderate activity was found in 15% of cases. Severe activity was found in 45.6% of cases (fig: 1 a,b,c,d), P value < 0.05 for each, however there was no significant correlation between both groups (P value = 0.099). Table (1): correlation between caspase-3 immunostaining and grade of hepatitis activity in liver biopsy of studied cases Caspase-3 immunostaining Grade of Hepatic activity Group I(n=40) n (%) Group II ( n33) n (%) Minimal 10 (25%) 3 (9.1 %) Mild 7 (17.5%) 10 (30.3%) Moderate 11 (27.5%) 5 (15 %) Severe 12(30%) 15 (45.6%) X2 P Chi-Square: P- value 0.099
4 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October A B C D Figure 1: Liver biopsy of HCV showed mild activity in group I (H&E X100) (a), the hepatocytes were positive for caspase-3 immunostaining; 75% of cells were scored +++ (b). Liver biopsy of HCV showing mild activity in group II (H&E X200) (c), 50 % of hepatocytes were positive for caspase 3 scored as ++ (x400) (d). Fibrosis of different stages 0-6 was diagnosed by Masson trichrome stain. The relation between caspase-3 and the stage of fibrosis was tabulated in table 2. It was notable that caspase-3 was expressed more in cases with fibrosis stages 4, 5 and 6 in both groups (statistically insignificant p value > 0.05) (fig:2 a,b). Table (2): correlation between caspase-3 immunostaining and stage of fibrosis in liver biopsy of studied cases Caspase-3 immunostaining Group I(n=40) n (%) Group II ( n33) n (%) Stage of fibrosis 0 1 ( 2.5 % ) 3 (9.1 %) 1 6 ( 15 % ) 5 ( 15.1%) 2 3 ( 7.5 %) 4 ( 12.2%) 3 8 ( 20%) 4 ( 12.2%) 4 5 (12.5%) 5 (15.1%) 5 9 ( 22.5%) 7 ( 21.2%) 6 8 ( 20%) 5 ( 15.1%) X2 P Chi-Square: P- value Hepatocytes didn't reveal positivity for Bcl2.We noted Bcl2 positive cells in the areas of inflammatory infiltrate, these cells being most likely lymphocytes (fig 2, c)
5 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October A B C Figure 2: Liver biopsy of HCV, showing cirrhosis (stage 6) (masson trichrome X200), the hepatocytes showed positive caspase-3 immunostaining score++++ (X400) (b), negative immunoreaction for bcl2, the inflammatory cells were positive (X400) (c). DISCUSSION Hepatitis C viral infection is a major cause of liver disease, characterized by inflammation, cell damage and fibrotic reaction of hepatocytes.there is increasing evidence suggesting that liver cell damage in chronic HCV infection is mediated by induction of apoptosis. (Bantel and Schulze-Osthoff., (2003) The morphological alterations of apoptosis are mediated by a family of intracellular proteases called caspases.(los et al., 1999) Caspase- 3 is the central executioner of many if not all apoptosis pathway. (Van Molle et al. (1999) In the present study apoptosis could not be seen by H&E Stains. By immunohistochemistry caspase- 3 activity in liver tissue was detected as brown stains in cell cytoplasm of chronic HCV liver tissue with positive correlation to the grade of activity; regardless the intensity of the stain. These finding were in agreement with previous studies by Ibrahim (2004) who obtained a direct evidence for variable degree of liver cell apoptosis in the liver of patients with chronic HCV and a significant correlation was found between the amount of apoptosis, expressed as apoptotic index and inflammatory activity in the liver. Also the results of the present study are in agreement with Bantel et al, (2001) who found that liver cell damage in chronic HCV infection is mediated by induction of apoptosis. Caspases are activated in human biopsy specimens of chronic hepatitis patients, activation of Caspase- 3 correlated significantly with inflammatory activity. Similar results were also found by Bantel et al., (2004) who found that chronic HCV infection is characterized by massive caspase activation, hepatocytes exhibiting immunoreactivity for active caspases and apoptotic features. So, they suggested that measurement of caspase-3 activation may be a suitable marker for detecting very early signs of liver damage. Although the pattern of HCV/schistosomal infection frequent in many geographic areas previous reports showed more severe liver disease in co-infected patients, the inter-actions between HCV and schistosomal infection are not fully understood.(kamal et al.,2000) In the present study, no significant difference was found between co-infected patients in group I and mono- infected patients in group II as regard liver disease severity. This was in agreement with Blanton et al., (2002) study in Egypt, who found that there was no interaction between schistosomal infection or disease and the prevalence and severity of hepatitis C. For both infections, the intensity or prevalence of infections was a poor predictor of morbidity. The prevalence of chronic liver disease in the Egyptian population from different pathogens suggests a generalized susceptibility to inflammatory liver disease. In the present study caspase-3 was expressed with higher stages of fibrosis (4, 5, and 6) with slight higher incidence in cases associated of schistosomiasis statistically insignificant. Anglico et al., (1997) and Kamal et al., (2000) stated that patients with concomitant schistosoma and HCV infection have higher incidence of cirrhosis and hepato-cellular carcinoma than patients with chronic HCV mono-infection, matched for age, disease duration, and HCV genotype. Kamal et al., (2000) found that, fibrosis was significantly accelerated in co-infected patients than mono-
6 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October infected patients and explained the cause of fibrosis progression by additive effects of 2 injurious agents or the difference in immune response and alteration of host signaling pathway inflicted by schistosomal infection, resulting in fibrogenesis. The results of the current study may be explained on the basis of the small number of the studied cases. The effect of co-infection of HCV and Schistosomiasis need long term follow up, which is not included in the current study. Repeated courses of antischistosomal therapy which is a very common attitude in Egyptians may greatly diminish the effect of schistosomal infection. As regards immunoreactivity for Bcl2 in liver biopsies taken from patients with chronic hepatitis C from both groups I and II, hepatocytes didn't reveal positivity for Bcl2. We noted Bcl2 positive cells in the areas of inflammatory infiltrate, these cells being most likely lymphocytes. Several studies have shown that proteins of the Bcl2 family are important regulators of apoptosis. They integrate various signals for survival or cell death generated within or outside the cells, the reaction between pro-and anti-apoptotic members of this family setting limits that cause cell death or survival. (Burlacu, 2003 and Borner, 2003) Our results regarding the expression of Bcl2 protein are consistent with those obtained in other studies which have revealed that this protein is not expressed or have negligible expression in hepatocytes in patients with hepatitis (Tsamandas et al., 2003 and Sarfraz et al., 2008), but in contradiction with those studies saying that Bcl2 is expressed in the cytoplasm of hepatocytes in chronic liver disease. (Chen et al., 2004) Conclusion: Caspase-3 is a noninvasive measure for detection of early liver cell injury and fibrosis.finding that the anti-apoptotic protein Bcl2 was not expressed in hepatocytes in patients with chronic hepatitis C leads to the conclusion that apoptosis is not inhibited by this protein, fact that could explain the increased apoptosis observed in liver samples from these patients. REFERENCES 1. Angelico ME, Rengansthan CG, Gandin, et al., (1997): Chronic liver disease in the Alexandria governorate, Egypt contribution of schistosomiasis and hepatitis virus infection. J Hepatology; 26: Bantel H., Lugering A., Porembo C. (2001): Caspase activation correlated with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology; 34 (4): Bantel H., Schultze-Osthoff K. (2003): Apoptosis in hepatitis C virus infection. Cell death diff; 10: Bantel H., Lugering A., Heidemann I., et al., (2004): Detection of apoptosis caspases activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology; 40: Blanton R.E., Salam E.A., Katiuki H.C., et al., (2002): Population- based difference in schistosomsa- mansoni and hepatitis C induced disease. J Infect Dis ;185 (11) : Borner C. (2003): The Bcl-2 protein family: sensors and checkpoints for lifeor-death decision. Mol.Immunol; 39: Burlacu A. (2003): Regulation of apoptosis by Bcl-2family proteins. J.Cell.Mol. Med; 7(3): Chen N.L.,Bai L., Chen P.l.,Zhang, Ch., et al., (2004): Apoptosis pathways of liver cells in chronic hepatitis.world J.Gastroentrol; 10 (21): Fisher R., Baumert Th., Blum H. (2007): Hepatitis C viral infection and apoptosis. World J.Gastroentrol; 13 (36): Frank C., Mohamed M.K., Strickland K.T., et al., (2000): The role of parenteral anti-schitosomal therapy in the spread of HCV in Egypt. Lancet;355: Garrido C., Galluzzi L., Brunet M., Puig P.E., et al.,(2006): Mechanism of cytochrome c release from mitochondria. Cell death diff ;13: Gupta S. (2003): Molecular signaling in death receptor and mitochondrial pathways of apoptosis.int. J. Oncol;
7 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October : Hengartner M. (2000): Biochemistry of apoptosis. Nature; 407: Ibrahim R. (2004): Liver cell apoptosis in Egyptian patients with chronic hepatitis C.M D thesis.cairo University. 15. Kamal S. M., Madwar M. A., Peter T., et al., (2000): Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatology; 32: Los M., Wesslbong S., Schulez-Osthoffk (1999): The role of caspases in development, immunity and apoptotic signal transduction lessons from knockout mice.immunity;10: Pearlman B.L. (2004): Heaptitis C infection: a clinical review. South Med J, 97(4) Rasola A., Bernardi P. (2007): The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis., Tran G. (2008): The role of hepatitis C virus in the pathogenesis of hepatocellular carcinoma. Bioscince Hrizons;1(2): Tsamandas A.C., Thomopoulos C., Zolota V., Kourelis Th., et al., (2003): Potential role of Bcl-2 and Bax mrna and protein expression in chronic hepatitis type B and C ;A clinico,pathological study. Mol.Path; 16 (12): Van Mole W., Deecker G., Rodriguez I., et al., (1999): Activation of caspases in lethal experimental hepatitis and prevention by acute phase protein.j Immunol; 163:
8 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October
"Lucian Blaga"University Sibiu Faculty of Medicine Victor Papilian. EVALUATION OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C. PhD thesis abstract
"Lucian Blaga"University Sibiu Faculty of Medicine Victor Papilian EVALUATION OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C. PhD thesis abstract Scientific coordinator Prof. Dr. Mircea DEAC PhD student
Hepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
Molecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
Liver Disease and Therapy of Hepatitis B Virus Infections
Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin
Transmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
BACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
The Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago [email protected] Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
HCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
Hepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
Viral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
Ishak versus METAVIR: Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C
10 Ishak versus METAVIR: Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C Gamal Shiha and Khaled Zalata Internal medicine department & pathology department, Mansoura
NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS C A CLINICAL STUDY
OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS C A CLINICAL STUDY By Prof. Dr. Mohamed Nabil Mawsouf*, **, Dr. Taha Tarek Tanbouli**& Dr.Wagdy Ibrahim El-Tayar** * Cancer Institute, Cairo University **
Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
HEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
Cirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
Albumin. Prothrombin time. Total protein
Hepatitis C Fact Sheet February 2016 www.hepatitis.va.gov Laboratory Tests and Hepatitis If you have hepatitis C, your doctor will use laboratory tests to about learn more about your individual hepatitis
Autoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
Alanine aminotransferase (serum, plasma)
Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase
HBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics
Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex
2015 Outpatient Chronic Hepatitis B Management
2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis
New IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
Notch 1 -dependent regulation of cell fate in colorectal cancer
Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases M. Trauner, Division of Gastroenterology and Hepatology, Department of Internal Medicine, MUG Co- Investigator: H. Samonigg,
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
Viral Hepatitis. 2009 APHL survey report
Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories
Update on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
Commonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
Antioxidant response in patients with chronic hepatitis B or C.
Antioxidant response in patients with chronic hepatitis B or C. Kamila Wójcik, Anna Piekarska, Elżbieta Jabłonowska Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland
2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements
Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase
Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
The Natural History of Chronic Hepatitis B Virus Infection
The Natural History of Chronic Hepatitis B Virus Infection Brian J. McMahon, M.D. 1 ABSTRACT Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic
Hepatitis C Infections in Oregon September 2014
Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with
THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
Knowledge about Post-exposure Prophylaxis for Hepatitis B Virus among Dentists and Dental Students in Pakistan
{189} ORIGINAL RESEARCH Knowledge about Post-exposure Prophylaxis for Hepatitis B Virus among Dentists and Dental Students in Pakistan Zohaib Ahmed 1 Umber Zahra 2 Nasir Saleem 3 1,2 BDS. House Officer.
Co-infected health-care workers
Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care
Review: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
Comparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases
Available online at wwwpelagiaresearchlibrarycom European Journal of Experimental Biology, 2013, 3(2):280-284 ISSN: 2248 9215 CODEN (USA): EJEBAU Comparative Levels of ALT, AST, ALP and GGT in Liver associated
2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
INFORMATION ABOUT HEPATITIS C
INFORMATION ABOUT HEPATITIS C PATIENT BOOKLET Index 1 About Hepatitis C About Hepatitis C Page 1 Hepatitis C Transmission Page 3 Hepatitis C Disease Progression Page 4 Hepatitis C Diagnosis and Treatment
3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.
April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the
Treatment of Acute Hepatitis C
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
General presentation
Cantacuzino National Institute of Research-Development for Microbiology and Immunology General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology (NIRDMIC)
Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice
Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Dr Chris Ford GP & SMMGP Clinical Lead Kate Halliday Telford & Wrekin Shared Care Coordinator Aims Discuss:
Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D.
Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China Title Charles Wang, M.D. Background Hepatitis C infects 170 million worldwide & 3 million Chinese HIV infects 33.3 million worldwide & 740,000
Indications in Hepatology and Liver Diseases
exclusively working in Health Care sananet GmbH Tilo Stolzke Breite Str. 6-8 23562 Lübeck Germany Telefon : +49 451 400 8301 Telefax : +49 451 400 8302 E-Mail : [email protected] Internet : www.sananet.com
Clinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
Approach to Abnormal Liver Tests
Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School
CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA
CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA WHAT IS CANCER OF THE LIVER? Hepatocellular carcinoma is the most common form and it comes from the main type of liver cell, the hepatocyte. About 3 out 4
Immunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany
Services & Products Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany Phone Europe: +49-40-41 33 83-0 Fax Europe: +49-40-41 33 83-14 Phone USA: +1-301-588-4650 [email protected] www.indivumed.com
HEPATITIS C. The Facts. Get Tested. Get Cured! Health
HEPATITIS C The Facts Get Tested. Get Cured! Health EVEN IF YOU FEEL HEALTHY, HEPATITIS C MAY BE DAMAGING YOUR LIVER. Your liver keeps you healthy in many ways, such as by removing toxins from your blood
HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
Hepatitis C. Laboratory Tests and Hepatitis C
Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what
Disclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
UCLA Asian Liver Program
CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,
PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN?
PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN? John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology
CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma
CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta
Sovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version)
Journal of Hepatology 38 (2003) 533 540 Special article EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version) The EASL Jury*
Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide
Newly Diagnosed: HEPATITIS C American Liver Foundation Support Guide T he American Liver Foundation's mission is to facilitate, advocate, and promote education, support, and research for the prevention,
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
Psoriasis; a new marker for Hepatitis C among Egyptian Patients
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 761-767 http://www.ijcmas.com Original Research Article Psoriasis; a new marker for Hepatitis C among Egyptian Patients Asmaa E Mohamed 1, Samaa A Taha 2, Amal
Update on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
Drugs Believed Capable of Inducing Autoimmune Hepatitis
Drugs Believed Capable of Inducing Autoimmune Hepatitis Leonard B. Seeff, M.D. National Institutes of Diabetes and Digestive and Kidney Diseases National Institutes of Health Immune-Mediated Liver Diseases
LIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
National Health Burden of CLD in Italy
National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /
Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head
New Approaches to a Major Public-Health Problem Infectious Diseases Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head Overview The Burden Of Infectious Disease Is Large And May
Non Alcoholic Steato-Hepatitis (NASH)
Non Alcoholic Steato-Hepatitis (NASH) DISCLAIMER NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY AND OR DAMAGE TO PERSONS OR PROPERTY ARISING FROM THIS WEBSITE AND ITS CONTENT.
Summary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
